Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces its results for the fourth quarter and full year 2020. A live webcast presentation by Nordic...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial ... BIOPHYTIS SAFebruary 17, 2021 GMT Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory Authorities These approvals follow the previous authorizations obtained from Brazil and the United States in most clinical centers Interim Analysis of Part 1 is expected in Q1 2021 Results from the full study (Part 1 and Part 2) are expected i...
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium - read this article along with other careers information, tips and advice on BioSpace
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium February 17, 2021 02:00 ET | Source: BIOPHYTIS SA BIOPHYTIS SA Romainville, FRANCE Clinical centers in France and Belgium will begin recruitment for Part 2 of the COVA Study following authorization from Regulatory Authorities These approvals follow the previous authorizations obtained from Brazil and the United States in most clinical centers Interim Analysis of Part 1 is exp...
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Patient recruitment in Part 2 of the COVA Study will begin in most clinical centers in Brazil and the United States Interim Analysis of Part 1 is expected in Q1 2021 Results from the full study (Part 1 and Part 2) are expected in Q2 2021 /EIN News/ -- PARIS and CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerat...